Login / Signup

Graves-PCD: protocol for a randomised, dose-finding, adaptive trial of the plasma cell-depleting agent daratumumab in severe Graves' disease.

Faye WolstenhulmeIrena BibbyMichael ColeLydia GrixtiNaomi McGregorPenny BradleyRebecca H MaierJenn WalkerSimon H PearceJames M S Wason
Published in: BMJ open (2024)
ISRCTN81162400.
Keyphrases
  • clinical trial
  • study protocol
  • randomized controlled trial
  • open label
  • phase iii
  • single cell
  • multiple myeloma
  • cell therapy
  • double blind
  • early onset
  • placebo controlled
  • stem cells
  • bone marrow